Revenue
2018
2019
2020
2021
2022
2023
2024
2025
CytomX Therapeutics, Inc. (CTMX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M | $37.3M | $68.4M | $26.9M | $59.5M | $71.6M | $12.8M | $7.7M | $5.1M | $888,000 |
| Research & development | $68.7M | $83.4M | $77.7M | $111.6M | $114.2M | $112.9M | $131.6M | $103.9M | $92.3M | $54.8M | $28.4M | $28.3M | $10.9M |
| Operating expenses | $98.6M | $113.1M | $107.7M | $154.5M | $153.4M | $149.0M | $168.4M | $137.4M | $117.9M | $74.6M | $40.9M | $34.8M | $15.8M |
| Operating income | −$22.4M | $25.0M | −$6.5M | −$101.3M | −$116.0M | −$80.5M | −$141.5M | −$77.9M | −$46.3M | −$59.6M | −$33.2M | −$29.8M | −$15.0M |
| EBITDAderived | −$21.0M | $26.7M | −$4.3M | −$98.9M | −$113.3M | −$78.0M | −$138.8M | −$76.0M | −$44.6M | −$57.9M | −$32.0M | −$29.0M | −$14.3M |
| Net income | −$17.4M | $31.9M | −$569,000 | −$99.3M | −$115.9M | −$64.8M | −$132.8M | −$84.6M | −$43.1M | −$58.9M | −$35.4M | −$30.3M | −$15.1M |
| Basic EPSper diluted share | — | — | — | — | — | — | — | — | -$1.16 | -$1.63 | -$4.90 | -$35.25 | -$24.46 |
| Diluted EPSper diluted share | — | — | — | — | — | — | — | — | -$1.16 | -$1.63 | -$4.90 | -$35.25 | -$24.46 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 | Ogden ChristopherChief Financial Officer | SellCommon Stock | 1.6K | $3.05 | $5.0K | 295.3K |
| Mar 17, 2026Form 4 | Chu Yu-WayeChief Medical Officer | SellCommon Stock | 21.3K | $6.42 | $136.6K | 189.4K |
| Mar 17, 2026Form 4 · 10b5-1 | McCarthy Sean A.CEO | SellCommon Stock | 119.0K | $6.42 | $763.8K | 1.08M |
| Mar 17, 2026Form 4 | BELVIN MARCIASVP, Chief Scientific Officer | SellCommon Stock | 31.5K | $6.42 | $202.2K | 300.8K |
| Mar 17, 2026Form 4 | Ogden ChristopherChief Financial Officer | SellCommon Stock | 19.3K | $6.42 | $124.1K | 296.9K |